Clinical Trial Update: Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

An update on safety and efficacy of a BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma from Phase 1/Phase 2 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA-targeted CAR-T therapy

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1, Phase 2 | Status: UNKNOWN